EUVIMEDEUVIMED entdecken
Editorial

FDA approves gene therapy for Wiskott-Aldrich syndrome

Hans D Ochs

Journal of Allergy and Clinical Immunology · 2026-06 · 157 (6) · 1256-1257

DOI: 10.1016/j.jaci.2026.04.003 ↗

Kurz gefasst

Editorial in der Zeitschrift Journal of Allergy and Clinical Immunology, 2026-06. Verfasst von Hans D Ochs. Beteiligte Einrichtung: Center for Immunity and Immunotherapies, Seattle Children's Research Institute, University of Washington, Seattle, Wash. Electronic address: Hans.och…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

FDA approvalWaskyraWiskott-Aldrich syndromeetuvetidigene autotemcelgene therapylentiviral vectorlogistic challenges

Autor:innen und Institutionen

  • Center for Immunity and Immunotherapies, Seattle Children's Research Institute, University of Washington, Seattle, Wash. Electronic address: Hans.ochs@seattlechildrens.org.

Zitieren

APA

Ochs, H. D. (2026). FDA approves gene therapy for Wiskott-Aldrich syndrome. Journal of Allergy and Clinical Immunology, 157(6), 1256-1257. https://doi.org/10.1016/j.jaci.2026.04.003

Vancouver

Ochs HD. FDA approves gene therapy for Wiskott-Aldrich syndrome. Journal of Allergy and Clinical Immunology. 2026;157(6):1256-1257. doi:10.1016/j.jaci.2026.04.003

BibTeX
@article{Ochs2026,
  author = {Ochs, Hans D},
  title = {FDA approves gene therapy for Wiskott-Aldrich syndrome},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2026},
  volume = {157},
  number = {6},
  pages = {1256--1257},
  doi = {10.1016/j.jaci.2026.04.003}
}
Kostenlos starten →